CCL4 News and Research

RSS

New study finds elevated inflammatory cytokines and lymphocytes linked to rare cases of myocarditis after COVID-19 vaccination

Researchers investigated a cohort of patients who developed myocarditis after SARS-CoV-2 mRNA vaccination.

10 May 2023

Nasal administration of a fully human anti-CD3 monoclonal antibody modulates T cell inflammatory responses in COVID-19

Researchers assessed the impact of an anti-CD3 monoclonal antibody called Foralumab in COVID-19 treatment.

9 Mar 2023

Self-directed autoantibodies against certain chemokines may protect against long-COVID

A recent study published in the journal Nature Immunology discovered autoantibodies against chemokines following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

8 Mar 2023

What is the association between natural killer cell dysfunction and COVID-19 disease severity?

Researchers assessed the association between natural killer cell dysfunction and COVID-19 disease severity.

20 Jul 2022

Innate and adaptive immune responses to SARS-CoV-2 infection in older golden hamsters

Researchers assessed the variation in SARS-CoV-2 manifestation with age.

13 Jun 2022

A comparison of SARS-CoV-2 and influenza cytokine storms

In a recent study published in the Journal of Interferon & Cytokine Research, researchers compared the cytokine storms of pandemic influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

9 Jun 2022

Role of SARS-CoV-2 S1 subunit in severe COVID-19

A new study aimed to determine whether portions of the SARS-CoV-2 spike protein are capable of activating innate immune cells like Gal-3.

30 Mar 2022

Researchers investigate SARS-CoV-2 specific inflammatory response

New research can confirm that while some of the response from monocytes to SARS-CoV-2 is generic to virus infection, most of it SARS-CoV-2 specific, especially proinflammatory responses.

7 Jan 2022

What genes affect the COVID-19 gender imbalance?

Many studies have established that coronavirus disease 2019 (COVID-19) is more infective in men than women, and men are more at risk of severe disease. While some have suggested that behavioral differences could explain increased transmission to men, this does not explain the more morbid prognosis.

16 Nov 2021

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Researchers look to gain an understanding of the mechanism of action of budesonide in improving the prognosis of patients with SARS-CoV-2 infection.

1 Nov 2021

The role of natural killer cells in fight against viral infections including SARS-CoV-2

In an effort to further understand the role of NK cells in combatting COVID-19, a group of researchers explored NK cells in acute viral infections, citing flavivirus and influenza virus infections as examples.

17 Jun 2021

Research looks at inflammatory nature of lipid nanoparticle component in mRNA vaccines

In a recent bioRxiv preprint research paper, Botond Z. Igyártó and colleagues from Thomas Jefferson University demonstrated the inflammatory nature of the lipid nanoparticles (LNPs).

15 Mar 2021

Immunologic modeling of COVID-19 severity and chronicity

In a new study by researchers at Universidad de Costa Rica and other institutions, a bioinformatics approach is used to determine whether Chronic COVID-19 (CC) might have a distinct immunologic signature compared to the mild to moderate (MM) or the severe/critical COVID-19.

24 Dec 2020

Researchers generate a transcriptomic map of the COVID brain

COVID-19 is known to be associated with multiple changes in gene expression, but many of these are also seen in chronic brain conditions as well as in some abnormal mental conditions. A recent study published on the preprint server bioRxiv in October 2020 uncovers the molecular basis of this association.

26 Oct 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

High-level quantum chemical computations help unravel underlying mechanism of hepatocellular toxicity

Balasubramanian and Basak have recently reported quantum chemical computations that enhance our understanding of mechanisms for the causes of liver toxicity. Hepatocellular carcinoma is one of the most common forms of cancer, and the primary cause has been attributed to liver fibrosis by chemical toxins, which is followed by liver cirrhosis.

9 May 2016

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients.

12 May 2015

Capsaicin has beneficial effects on liver damage, study reveals

Results revealed today at the International Liver Congress 2015 show that the daily consumption of capsaicin, the active compound of chilli peppers, was found to have beneficial effects on liver damage.

23 Apr 2015

Scientists potentially discover new therapeutic targets to halt progression of tumor cells

Chronic inflammation is directly associated with several types of cancer, yet the reasons as to why this happens at a cellular level remain unclear. Now, an international team of scientists led by researchers at The Wistar Institute has identified a multistep process showing not only how these cancers develop but also potentially discovering new therapeutic targets that could halt the formation and progression of tumor cells.

10 Feb 2015

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014